REVIEW
|
doi:10.20944/preprints202404.0944.v1
Subject:
Medicine And Pharmacology,
Immunology And Allergy
Keywords:
Immune checkpoint inhibitor; ipilimumab; pembrolizumab
Online: 16 April 2024 (03:30:17 CEST)
ARTICLE
|
doi:10.20944/preprints201811.0609.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
immune checkpoint inhibitors; immune-related adverse events (irAEs); tolerance; ipilimumab; nivolumab; interleukin-2; hyperthermia; low-dose-combination therapy
Online: 28 November 2018 (10:23:31 CET)
ARTICLE
|
doi:10.20944/preprints201808.0307.v3
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immune Checkpoint Inhibitors; anti-PD-1/PDL-1; anti-CTLA-4; gender; sex; Nivolumab; Pembrolizumab; Atezolizumab; Ipilimumab; Durvalumab
Online: 15 November 2018 (07:02:24 CET)
ARTICLE
|
doi:10.20944/preprints202311.0688.v1
Subject:
Biology And Life Sciences,
Biochemistry And Molecular Biology
Keywords:
melanoma; metastasis; overall survival; progression-free survival; side effects; Nivolumab; Ipilimumab; anti-programmed death-1 antibodies; anti-cytotoxic T-lymphocyte antigen-4 antibodies.
Online: 10 November 2023 (11:05:56 CET)